Endogenous Metabolite

目前正在研究5-氨基乙酰丙酸盐酸盐（ALA）（一种非荧光前药）是否能刺激恶性胶质瘤细胞中荧光卟啉的形成，从而用于术中肿瘤识别和切除。中位随访期为 35.4 个月（95% CI 1.0-56.7）。在接受 5-氨基乙酰丙酸治疗的 139 名患者中，有 90 名 (65%) 的所有对比增强肿瘤都被完全切除，而在接受白光治疗的 131 名患者中，只有 36 名 (36%) 出现了这种结果（组间差异为 29% [95% CI 17-40]，p < 0.0001）。接受 5-氨基乙酰丙酸治疗的患者的 6 个月无进展生存期高于接受白光治疗的患者（41.0% [32.8-49.2] vs 21.1% [14.0-28.2]；组间差异 19.9% [9.1] -30.7]，p= 0.0003，Z 检验）[1]。已经证明，5-ALA 本身不足以提供完全切除，且不会带来术后神经功能衰退的风险。此外，对于功能性 III 级神经胶质瘤，iMRI 与功能性神经导航相结合明显优于 5-ALA 切除方法 [2]。

尽管关于恶性胶质瘤细胞减灭术的争论仍在继续，但人们普遍认为，肿瘤减灭程度的增加可以提高总体生存率。然而，由于术中难以区分正常组织和病理组织，肿瘤切除范围的最大化受到阻碍。在此背景下，我们研究了两种已确立的肿瘤可视化方法，即5-ALA荧光引导手术和集成功能神经导航的术中MRI（iMRI），作为双术中可视化（DIV）方法。根据放射学表现，37名患者可能患有恶性胶质瘤（世界卫生组织III级或IV级）。iMRI确认了21个根据5-ALA技术显示完全切除的实验序列。iMRI无法确认14个根据5-ALA技术显示完整切除的序列，因为iMRI检测到了残留肿瘤。进一步的分析表明，这些序列可被归类为功能性II级肿瘤（邻近功能性脑区）。荧光引导切除和高场MRI术中评估的结合显著增加了该亚组邻近功能区的恶性胶质瘤的肿瘤切除范围，从61.7%增加到100%；仅5-ALA被证明不足以实现完全切除，而不会导致术后神经功能恶化的危险。此外，对于功能性III级胶质瘤，iMRI结合功能性神经导航明显优于5-ALA切除技术。切除范围可以从57.1%增加到71.2%，而不会导致术后神经功能缺损[2]。

检测97例ESCC患者病理标本中GPX4和HMOX1的表达，并进行预后分析。实时聚合酶链式反应（RT-PCR）、RNA微阵列和蛋白质印迹分析用于评估5-ALA在体外铁下垂中的作用。Ann Surg Oncol. 2021 Jul;28(7):3996-4006. https://pubmed.ncbi.nlm.nih.gov/33210267/

Dual Intraoperative Visualization (DIV) protocol[2]
Tumor volumetry was performed immediately prior to surgery. Tumor resection was then performed using the 5-ALA signal alone with the absence of a visible signal defining completeness of resection. This determination was carried out by the primary surgeon at all times. Functional neuronavigation data was intermittently projected to prevent inadvertent damage to functional brain areas. At the end of each stage of resection, the tumor cavity was systematically inspected to exclude residual tumor. Once the 5-ALA signal was undetectable, an iMRI scan was performed. If the extent of resection was confirmed, the decision to conclude the surgery was taken by the primary surgeon. Otherwise, the residual tumor volume was re-segmented and resection continued according to the neuronavigation. In all such cases the 5-ALA signal was redetected during further surgery once either the thin intervening layer of “healthy” brain parenchyma was removed and/or the viewing angle subsequently optimized. This procedure was repeated until the 5-ALA signal was no longer detectable, and the corresponding absence of contrast-enhancing tumor corroborated by iMRI. The additionally resected tissue detected by the iMRI was also analyzed by an experienced neuropathologist, confirming pathological glioma cell infiltration. In the event of persistence of 5-ALA in areas shown to be functional by the neuronavigation data, further surgery in the corresponding direction was intentionally terminated.

---

In addition, this study used ferrostatin-1, a ferroptosis inhibitor, and a lipid peroxidation reagent against cell lines treated with 5-ALA. Finally, the role of 5-ALA was confirmed by its effect on an ESCC subcutaneous xenograft mouse model. Ann Surg Oncol. 2021 Jul;28(7):3996-4006. https://pubmed.ncbi.nlm.nih.gov/33210267/

Absorption
Oral bioavailability is 50-60%. ### Topical Gel In a trial involving 12 adult subjects with mild to moderate actinic keratosis (AK) and at least 10 AK lesions on the face or forehead, the pharmacokinetics (PK) of aminolevulinic acid (ALA) and protoporphyrin IX (PpIX) were evaluated. Subjects received a single application of one tube of ALA (2 g) under closed-circuit conditions for 3 hours, followed by photodynamic therapy (PDT) covering a total area of 20 cm². The mean ± standard deviation of baseline plasma ALA and PpIX concentrations were 20.16 ± 16.53 ng/mL and 3.27 ± 2.40 ng/mL, respectively. In most subjects, plasma ALA concentrations increased by up to 2.5-fold within the first 3 hours after ALA application. The mean ± standard deviation area under the concentration-time curve (AUC0-t) and maximum concentration (Cmax) of ALA (n=12) after baseline correction were 142.83 ± 75.50 ng·h/mL and 27.19 ± 20.02 ng/mL, respectively. The median time to reach Cmax (Tmax) was 3 hours. ### Topical Solution Two human pharmacokinetic (PK) studies were conducted in subjects with mild to moderate actinic keratosis of the upper extremities, with at least 6 lesions on one upper extremity and at least 12 lesions on the other. The single-dose regimen consisted of two topical applications of ALA solution (each containing 354 mg ALA HCl) directly to the lesion site, followed by a 3-hour occlusion before phototherapy. The first PK study included 29 subjects and assessed the PK parameters of ALA. The baseline-corrected mean ± standard deviation of the maximum concentration (Cmax) of ALA was 249.9 ± 694.5 ng/mL, and the median time to peak concentration (Tmax) was 2 hours after administration. The mean exposure to ALA (expressed as area under the concentration-time curve (AUCt)) was 669.9 ± 1610 ng·hr/mL. The mean elimination half-life (t1/2) of ALA was 5.7 ± 3.9 hours. A second pharmacokinetic (PK) study was conducted in 14 subjects, and PK parameters for ALA and PpIX were determined. In 50% (7/14) of the subjects, the baseline-corrected PpIX concentration was negative in at least 50% of the samples, so the AUC could not be reliably estimated. The baseline-corrected mean ± standard deviation of Cmax for ALA and PpIX were 95.6 ± 120.6 ng/mL and 0.95 ± 0.71 ng/mL, respectively. The median time to peak concentration (Tmax) for ALA and PpIX was 2 hours and 12 hours after administration, respectively. The mean AUCt for ALA was 261.1 ± 229.3 ng·hr/mL. The mean half-life (t1/2) for ALA was 8.5 ± 6.7 hours. ### Oral Solution In 12 healthy subjects, the absolute bioavailability of ALA after administration of the recommended dose of ALA solution was 100.0% ± 1.1, ranging from 78.5% to 131.2%. The median time to peak plasma concentration of ALA was 0.8 hours (range 0.5–1.0 hours).
Route of Excretion
In 12 healthy subjects, the rate of maternal ALA excretion in urine within 12 hours following administration of the recommended dose of aminolevulinic acid (ALA) solution was 34 ± 8% (mean ± standard deviation), ranging from 27% to 57%.
Volume of Distribution
In healthy volunteers, the volume of distribution of aminolevulinic acid was 9.3 ± 2.8 L for intravenous administration and 14.5 ± 2.5 L for oral administration. [11961050]

---

Metabolism/Metabolites
Exogenous aminolevulinic acid (ALA) is metabolized to protoporphyrin IX (PpIX), but the proportion of ALA metabolized to PpIX is unknown. The mean plasma AUC of PpIX is less than 6% of that of ALA. Following topical administration, the drug is synthesized in situ into protoporphyrin IX within the skin. Half-life: The mean half-life after oral administration was 0.70 ± 0.18 hours, and the mean half-life after intravenous administration was 0.83 ± 0.05 hours. Biological half-life: The mean elimination half-life (t1/2) of the topical aminolevulinic acid solution was 5.7 ± 3.9 hours, and the mean half-life of the oral solution was 0.9 ± 1.2 hours. In another pharmacokinetic study involving 6 healthy volunteers, using a 128 mg dose, the mean half-life after oral administration was 0.70 ± 0.18 hours, and the mean half-life after intravenous administration was 0.83 ± 0.05 hours.

Toxicity Overview
Based on the hypothesized mechanism of action, photosensitization following topical application of aminolevulinic acid (ALA) solution is achieved through the metabolism of ALA into protoporphyrin IX (PpIX), which accumulates in the skin where aminolevulinic acid is applied. Upon exposure to light of appropriate wavelength and energy, the accumulated PpIX undergoes a photodynamic reaction, a cytotoxic process dependent on the simultaneous presence of light and oxygen. Light absorption leads to the excited state of the porphyrin molecule, followed by spin shift of PpIX towards molecular oxygen to generate singlet oxygen, which can further react to generate superoxide anions and hydroxyl radicals. The use of aminolevulinic acid for photosensitization of actinic keratosis lesions, combined with irradiation using the BLU-UTM blue light photodynamic therapy device (BLU-U), forms the basis of aminolevulinic acid photodynamic therapy (PDT).

---

Effects during Pregnancy and Lactation
◉ Overview of Use During Lactation
Currently, there is no information regarding oral administration of aminolevulinic acid during lactation. To minimize infant exposure, breastfeeding should be suspended for 24 hours after oral administration. Due to extremely low systemic absorption, breastfeeding is not expected to result in local exposure of the infant to aminolevulinic acid. Aminolevulinic acid-induced photodynamic therapy has been successfully used to treat various nipple skin lesions. This therapy appears to help maintain nipple anatomy, thus facilitating breastfeeding.
◉ Effects on breastfed infants
No relevant published information found as of the revision date.
◉ Effects on breastfeeding and breast milk
No relevant published information found as of the revision date.

---

Route of administration
Oral bioavailability is 50-60%.

---

Protein binding
In in vitro studies, after using aminolevulinic acid (ALA) at concentrations reaching approximately 25% of the maximum plasma concentration of ALA solution at the recommended dose, the average protein binding rate of ALA was 12%.

[1]. Stummer, W., et al., Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol, 2006. 7(5): p. 392-401.
[2]. Eyupoglu, I.Y., et al., Improving the extent of malignant glioma resection by dual intraoperative visualization approach. PLoS One, 2012. 7(9): p. e44885.

5-Aminolevulinic acid salt is the monohydrochloride salt of 5-aminolevulinic acid. It is metabolized to protoporphyrin IX, a photosensitizing compound that accumulates in the skin. It is used in conjunction with blue light irradiation to treat mild to moderate actinic keratosis of the face or scalp. It has a dual role as an antitumor drug, photosensitizer, dermatological drug, and prodrug. It contains 5-aminolevulinic acid.
Aminolevulinic acid salt is the hydrochloride form of aminolevulinic acid (an aminoketone) used for topical photosensitization therapy. Aminolevulinic acid (ALA) is a metabolic prodrug that can be converted into the photosensitizer protoporphyrin IX (PpIX), which accumulates intracellularly. When exposed to light of an appropriate wavelength (red or blue), PpIX catalyzes the production of singlet oxygen, an endotoxin that can further react to generate superoxide anions and hydroxyl radicals. This leads to cytotoxic effects.
PpIX is an intermediate compound produced from succinyl-CoA and glycine during heme synthesis. It is used as a photochemotherapy for actinic keratosis.

---

Drug Indications
Gliolan is indicated for adult patients for visualization of malignant tissue during surgery for malignant gliomas (WHO Grade III and IV).
For the treatment of mild to moderate actinic keratosis (Olsen Grade 1 to 2; see Section 5.1) of the adult face and scalp, as well as cancerous areas. This study aims to explore treatment options with 5-aminolevulinic acid for adult patients with superficial and/or nodular basal cell carcinoma who are unsuitable for surgical treatment due to potential treatment-related complications and/or poor cosmetic outcomes.

---

Background: 5-Aminolevulinic acid is a non-fluorescent prodrug that can lead to the accumulation of fluorescent porphyrins within malignant glioma cells—a finding being used for intraoperative identification and resection of these tumors. This study aims to evaluate the impact of fluorescence-guided resection using 5-aminolevulinic acid on tumor radicality, progression-free survival, overall survival, and complications. Methods: 322 patients aged 23 to 73 years with suspected malignant gliomas and suitable for complete enhanced tumor resection were randomly assigned to two groups: one group received fluorescence-guided resection with 20 mg/kg body weight of 5-aminolevulinic acid (n=161), and the other group received conventional white light microsurgery (n=161). The primary endpoint was the number of patients with no enhancement on early MRI (i.e., MRI performed within 72 hours postoperatively) and 6-month progression-free survival as assessed by MRI. Secondary endpoints included residual tumor volume on postoperative MRI, overall survival, neurological deficits, and toxicities. We report the results of an interim analysis that included 270 patients (139 treated with 5-aminolevulinic acid and 131 treated with white light), excluding patients whose histological and radiological results, as assessed by the center reviewer (unaware of the treatment allocation), did not meet the inclusion criteria; the interim analysis results led to the termination of the study according to the protocol. Both the primary and secondary endpoints were analyzed in the full analysis population using an intention-to-treat approach. This study was registered at http://www.clinicaltrials.gov, registration number NCT00241670. Results: The median follow-up time was 35.4 months (95% CI 1.0–56.7). Of the 139 patients treated with 5-aminolevulinic acid, 90 (65%) of enhancing tumors were completely resected; compared to only 47 (36%) of the 131 patients treated with white light therapy (between groups: 29% [95% CI 17–40], p<0.0001). Patients treated with 5-aminolevulinic acid had a longer 6-month progression-free survival than those treated with white light therapy (41.0% [32.8–49.2] vs 21.1% [14.0–28.2]; between groups: 19.9% [9.1–30.7], p=0.0003, Z-test). There were no differences among the groups in the frequency of serious adverse events or adverse events of any organ system category reported within 7 days postoperatively. Conclusion: Tumor fluorescence derived from 5-aminolevulinic acid can more thoroughly remove enhancing tumors, thereby improving progression-free survival in patients with malignant gliomas. [1]

---

Background: 5-aminolevulinic acid (5-ALA) is a natural amino acid widely used in cancer treatment due to its tumor-specific metabolic pathway characteristics. This study shows that 5-ALA induces ferroptosis through glutathione peroxidase 4 (GPX4) and heme oxygenase 1 (HMOX1) and has antitumor effects in esophageal squamous cell carcinoma (ESCC). Methods: The expression of GPX4 and HMOX1 in pathological specimens from 97 ESCC patients was detected and prognostic analysis was performed. The role of 5-aminolevulinic acid (5-ALA) in in vitro ferroptosis was evaluated using real-time polymerase chain reaction (RT-PCR), RNA microarray and Western blot analysis. Furthermore, this study also examined 5-ALA-treated cell lines using the ferroptosis inhibitor ferrostatin-1 and a lipid peroxidation reagent. Finally, the role of 5-ALA was further confirmed by its effect in a mouse model of subcutaneous xenograft esophageal squamous cell carcinoma (ESCC). The results showed that GPX4 upregulation and HMOX1 downregulation are factors contributing to poor prognosis in ESCC. In RNA microarray analysis of KYSE30 cells, ferroptosis was one of the most frequently induced pathways; 5-ALA treatment inhibited GPX4 expression and upregulated HMOX1 expression. These results were validated by RT-PCR and Western blotting experiments. In addition, 5-ALA leads to increased lipid peroxidation and exerts anti-tumor effects in various cancer cell lines, an effect that can be inhibited by the ferroptosis inhibitor ferrostatin-1. In vivo experiments showed that 5-ALA inhibits GPX4 expression and upregulates HMOX1 expression in tumor tissue, thereby leading to tumor volume reduction. Conclusion: 5-ALA induces ferroptosis in esophageal squamous cell carcinoma (ESCC) cells by regulating the expression of GPX4 and HMOX1. Therefore, 5-ALA may be a promising novel therapeutic agent for ESCC. Reference: Ann Surg Oncol. 2021 Jul;28(7):3996-4006.

C5H9NO3.H3O4P

229.12508

229.035

C, 26.21; H, 5.28; N, 6.11; O, 48.88; P, 13.52

868074-65-1

5451-09-2 (HCl);106-60-5 (free);868074-65-1 (phosphate);

24737828

Typically exists as solid at room temperature

167.96

5

8

4

14

171

0

O=C(CCC(CN)=O)O.O=P(O)(O)O

XWNWBYZHOAIHTK-UHFFFAOYSA-N

InChI=1S/C5H9NO3.H3O4P/c6-3-4(7)1-2-5(8)9;1-5(2,3)4/h1-3,6H2,(H,8,9);(H3,1,2,3,4)

5-amino-4-oxopentanoic acid;phosphoric acid

Aminolevulinic acid phosphate; 868074-65-1; 5-Aminolevulinic acid phosphate; Pentanoic acid, 5-amino-4-oxo-, phosphate (1:1); UNII-FM8DCR39GH; delta-Aminolevulinic acid phosphate; FM8DCR39GH; Aminolevulinic acid phosphate [INCI];

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。

---

注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。

View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

---

口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。

View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

---

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。